Skip to main content

Table 1 Baseline Characteristics

From: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

Characteristic Overall (N = 75) Infliximab + CS (N = 36) CS Alone (N = 39) P Value
Median Age (Interquartile Range)   63 years (50–71 years) 61 years (52–72 years) 0.633
Sex, No. (%)
 Male 50 (66.7) 29 (80.6) 21 (53.8) 0.016
 Female 25 (33.3) 7 (19.4) 18 (46.2) 0.016
Cancer Type, No. (%)
 Melanoma 53 (70.7) 29 (80.6) 24 (61.5) 0.167
 Genitourinarya 15 (20.0) 7 (19.4) 8 (20.5)  
 Head and Neck Cancer 1 (1.3) 0 1 (2.6)  
 Leukemia 1 (1.3) 0 1 (2.6)  
 Lung Cancer 2 (2.7) 0 2 (5.1)  
 Otherb 3 (4.0) 0 3 (7.7)  
Immunotherapy Type, No. (%)
 Ipilimumab 45 (60.0) 21 (58.3) 24 (61.5) 0.834
 Ipilimumab + Nivolumab 12 (16.0) 6 (16.7) 6 (15.4)  
 Nivolumab 4 (5.3) 1 (2.8) 3 (7.7)  
 Pembrolizumab 13 (17.3) 7 (19.4) 6 (15.4)  
 Tremelimumab 1 (1.3) 1 (2.8) 0  
Symptoms at Onset, No. (%)
 Diarrhea 73 (97.3) 36 (100) 37 (94.9) 0.494
 Nausea 21 (28.0) 8 (22.2) 13 (33.3) 0.315
 Vomiting 11 (14.7) 3 (8.3) 8 (20.5) 0.195
 Abdominal Cramps 32 (42.7) 13 (36.1) 19 (48.7) 0.351
 Blood in Stool 22 (29.3) 14 (38.9) 8 (20.5) 0.127
 Mucus in Stool 2 (2.7) 0 2 (5.1) 0.494
 Elevated WBC Counts 3 (4.0) 1 (2.8) 2 (5.1) 1
Pathology, No. (%)
 Positive 37 (49.3) 20 (55.6) 17 (43.6) 0.534
 Negative 6 (8.0) 2 (5.6) 4 (10.3)  
 Not Tested 32 (42.7) 14 (38.9) 18 (46.2)  
  1. aIncludes renal cell carcinoma, urothelial carcinoma, and prostate cancer
  2. bIncludes anal squamous cell cancer, pancreatic cancer, and glioblastoma
  3. CS corticosteroids, WBC White blood cells